Modifying Predictors of Adverse Maternal and Obstetric Outcomes in SLE

Contraception in SLE

Contraceptive choices for women with SLE are the same as for other women, although a number of medical concerns influence the decision. The 3 main classes of contraception are barrier methods, oral or implanted hormones, and intrauterine devices (IUDs).

Among women with SLE, contraception performs a dual function. In addition to preventing unwanted pregnancy, contraception is important to establish optimal timing of pregnancy to quiescent periods of disease to reduce the risk for lupus complications. Although contraceptive efficacy is always important, it is critical to the well-being of the woman with SLE.

A literature review by Yazdany and colleagues19 identified 1-year failure rates for barrier methods ranging from 15% to 21%. Failure rates for the cervical cap were as high as 32% in women who had previous term pregnancies. In comparison, the authors reported much lower failure rates for hormonal methods, ranging from 3% for medroxyprogesterone injection to 8% for the hormonal patch, ring, progestin-only, and combination estrogen-progestin oral contraceptives (OCs).19 The failure rate for IUD use is approximately 2% per year.16

Barrier methods

The majority of women with SLE who do use contraception use barrier methods, including male and female condoms, diaphragm with spermicide, and the cervical cap.17 Barrier methods are inexpensive, easily accessible, and associated with few complications; however, they are not highly effective. Because of the significant differences in contraceptive reliability among barrier methods, the Centers for Disease Control in 2010 recommended against the use of behavioral and barrier methods as the only contraception techniques.18

Special concerns about OCs in women with SLE

The use of OCs by women with SLE has been somewhat controversial for a number of reasons. The high prevalence of SLE among women of childbearing age strongly points to a hormonal interaction. Fluctuating hormones late in pregnancy have also been associated with SLE flares in some studies,20-22 contributing to the belief that hormonal contraceptives would include a similar risk. Therefore, estrogen-only formulations are generally contraindicated in these women.16 In 2010, Duarte and Ines reported on a number of studies that contradicted this risk. They concluded that, overall, data from multiple randomized controlled trials suggests that the use of low-dose combination OCs is unlikely to increase the risk for disease flares.20

A more significant concern with OC use is the increased potential for thromboembolic events. The presence of antiphospholipid antibodies is a common feature in SLE that already predisposes these women to thrombotic risk.23,24 Thrombolysis is reported to occur in 13.3% to 22% of those with SLE, and a 2016 study reported an incidence 27- to 43-fold higher than in the general population.25-29

Intrauterine Devices

The risks of IUD use are the same for those with SLE as for the general population. These include a 5% rate of device expulsion and the risk for irregular bleeding and infection post-insertion, making this method unsuitable for women with a history of lupus nephritis.16 IUDs must be replaced every 5 years, with careful monitoring during the time the device is used. If these concerns are managed, this method is a good choice for many women with SLE because it provides the highest degree of protection against pregnancy without the risk for disease flares associated with OCs.

Summary and clinical applicability

Contraceptive counseling is essential for women with SLE to select the safest, most reliable method to prevent immediate conception. Similarly, counseling is important to the planning of pregnancy to allow for conception at a quiescent period in SLE, which allows the best possibility to ensure an uneventful pregnancy and delivery of a healthy child.

All women who are being treated for SLE should be counseled routinely about the risks of unintended pregnancy and the opportunity to reduce these risks through effective contraception. Women who are planning to become pregnant should be monitored by their physician to reach a minimum period of 4 months of inactive disease before attempting conception.


1. Stojan G, Baer AN. Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol. 2012;8(5):439-453.

2. Peart E, Clowse ME. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol. 2014;26(2):118-123.

3. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54(3):899-907.

4. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199(2):127.e1-6.

5. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 2007;33(2):237-252.

6. Chakravarty EF, Colón I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol. 2005;192(6):1897-1904.

7. Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol. 2003;16(2):161-167.

8. Huong DL, Wechsler B, Vauthier-Brouzes D, Beaufils H, Lefebvre G, Piette JC. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis. 2011;60(6):599-604.

9. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5(11):2060-2068

10. Clowse ME, Magder LS, Witter F, Petri M. Early risk factors for pregnancy loss in lupus. Obstet Gynecol. 2006:107:293-299.

11. Mok CC, Wong RW. Pregnancy in systemic lupus erythematosus. Postgrad Med J. 2001;77(905):157-165.

12. Salmon JE, Hueser C, Triebwasser M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8(3):e1001013.

13. Buyon JP, Garabet L, Kim M, et al. Favorable prognosis in a large, prospective multicenter study of lupus pregnancies. Arthritis Rheum. 2011;63 Suppl 10:1707.

14. Imbasciati E, Tincani A, Gregorini G, et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant. 2009;24(2):519-525.

15. Bramham K, Hunt BJ, Bewley S, et al. Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J Rheumatol. 2011;38(9):1906-1913.

16. de Jesus GR, Mendoza-Pinto C, de Jesus NR, et al. Understanding and managing pregnancy in patients with lupus. Autoimmun Dis. 2015;2015:943490.

17. Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114(2 Pt 1):341-353.

18. Centers for Disease Control and Prevention. U. S. medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep. 2010;59(RR-4):1-86.

19. Yazdany J, Trupin L, Kaiser R, et al. Contraceptive counseling and use among women with system lupus erythematosus: a gap in health care quality? Arthritis Care Res (Hoboken). 2011;63(3):358-365.

20. Duarte C, Ines L. Oral contraceptives and systemic lupus erythematosus: what should we advise to our patients? Acta Reumatol Port. 2010;35(2):133-140.

21. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum. 1991;34(12):1538-1545.

22. Ruiz-Irastorza G, Lima F, Alves J, et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol. 1996;35(2):133-138.

23. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med. 1990;112(9):682-698.

24. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117(2):997-1002.

25. Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG, et al. Venous and arterial thrombotic events in systemic lupus erythematosus. J Rheumatol. 2016;43(3):576-586.

26. Sarabi ZS, Chang E, Bobba R, et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2005;53(4):609-612.

27. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum. 2005;52(9):2774-2782.

28. Chang ER, Pineau CA, Bernatsky S, Neville C, Clarke AE, Fortin PR. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. J Rheumatol. 2006;33(9):1780-1784.

29. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis. 2009;68(2):238-241